Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - VERENIUM CORP | d392295d8k.htm |
| EX-99.1 - PRESS RELEASE - VERENIUM CORP | d392295dex991.htm |
 Verenium Corporation
Q2 2012 Earnings Call
August 6, 2012
Exhibit 99.2 |
 Forward Looking Statements
Statements
in
this
presentation
that
are
not
strictly
historical
are
“forward-looking”
and
involve
a
high
degree
of
risk
and
uncertainty.
These
include,
but are not limited to, statements related to Verenium’s technology, products
and product candidates (including Verenium’s ability to identify,
develop and commercialize new products and product candidates, either independently
or with collaboration partners, and Verenium’s timetable for
doing
so),
lines
of
business,
markets
(including
market
size
and
Verenium’s
ability
to
identify,
develop
and
commercialize
products
to
address
those
markets),
operations
(including
Verenium’s
ability
to
successfully
negotiate
and
enter
into
collaboration
partnerships),
capabilities,
commercialization activities, customer adoption rates, industry conditions, future
financial performance, and near-term and longer-term growth and
prospects.
Such
statements
are
only
predictions,
and
actual
events
or
results
may
differ
materially
from
those
projected
in
such
forward-looking
statements. Factors that could cause or contribute to the differences include, but
are not limited to, risks associated with Verenium’s strategic focus,
technologies, products and product candidates (including Verenium’s ability to
identify, develop and commercialize new products and product
candidates,
either
independently
or
with
collaboration
partners,
and
market
demand
for
these
product
and
product
candidates),
dependence on patents and proprietary rights, protection and enforcement of its
patents and proprietary rights, the commercial prospects of the industries
in which Verenium operates and sells products, Verenium’s dependence on manufacturing and/or license agreements, its ability to
achieve
milestones
under
existing
and
future
collaboration
agreements,
the
ability
of
Verenium
and
its
partners
to
commercialize
its
technologies
and
products
(including
by
obtaining
any
required
regulatory
approvals)
using
Verenium’s
technologies,
the
timing
for
launching
any
commercial
products
and
projects,
the
ability
of
Verenium
and
its
collaborators
to
market
and
sell
any
products
that
it
or
they
commercialize,
the
development
or availability of competitive products or technologies, the future ability of
Verenium to enter into and/or maintain collaboration and joint venture
agreements and licenses on a timely basis or at all, and risks and other
uncertainties more fully described in Verenium’s filings with the Securities
and Exchange Commission, including, but not limited to, Verenium’s annual
report on Form 10-K for the year ended December 31, 2011 and any
updates
contained
in
its
subsequently
filed
quarterly
reports
on
Form
10-Q.
These
forward-looking
statements
speak
only
as
of
the
date
hereof,
and Verenium expressly disclaims any intent or obligation to update these
forward-looking statements. 2 |
 Agenda
1)
Janet Roemer, Chief Operating Officer
–
Second Quarter Commercial Operational Trends & Performance
2)
Jeff Black, Chief Financial Officer
–
Financial Results for the First Half of 2012
3)
James Levine, President & Chief Executive Officer
–
Key Growth Drivers Including:
i.
Current Commercial Products
ii.
Product Pipeline
iii.
Expansion Pipeline
3 |
 ANIMAL HEALTH AND NUTRITION
Lead Product, $310M+ Market
Verenium’s Unique Commercial Products
Near-term revenue growth driven from share gain in existing markets
GRAIN PROCESSING
$400M Market
OILFIELD SERVICES
Up to $270M* Combined Market In
Hydraulic Fracturing & Filter Cake
Removal
4
Source: Market size estimates based on Verenium internal estimates and research
reports including: BCC Research, “Global Markets for Enzymes in Industrial Applications”, March 2012, and L.
Hepner & Associates, “Industrial Enzymes for Starch, Dairy,
Detergents, Baking, Textiles, Food and Animal Feed”, February 2011.
*Total estimated market for all enzyme and chemical breakers.
Phyzyme®
XP Phytase is a registered trademark of Dansico Animal Nutrition, now owned
by DuPont. |
 Verenium’s Product Pipeline
(As of Q2 2012)
5
Product Candidate
Potential Market
Size (2016)*
Estimated
Launch
Target Market
Position
Next-Gen Phytase
$400 -
450M
2013 -
2015
Major
(1)
NSP Cocktail
(Non Starch Polysaccharides)
$200 -
250M
2013 -
2015
Major
Next-Gen Gluco-Amylase
$200 -
250M
2013 -
2014
Specialty
(2)
Process Enhancer
$15M
2012 -
2013
Major
Process Enhancer
$10M
2013 -
2014
Major
Starch Modifier
$5M
2013
Exclusive
(3)
Hyper-Thermostable Guar Breaker
Up to $250M
*
2012
Specialty
Next-Gen Guar Breaker
Up to $250M
*
2013
Specialty
Animal Health & Nutrition Enzymes
Grain Processing Enzymes
Oilfield Services Enzymes
Source: Market size estimates based on Verenium internal estimates and research
reports including: BCC Research, “Global Markets for Enzymes in Industrial Applications”, March 2012, and L.
Hepner & Associates, “Industrial Enzymes for Starch, Dairy,
Detergents, Baking, Textiles, Food and Animal Feed”, February 2011.
*Total estimated market for all enzyme and chemical breakers
(1)
We define Major market position as 20-30% targeted market penetration at
maturity (2)
We define Specialty market position as 5-10% targeted market penetration at
maturity (3)
We
define
Exclusive
market
position
as
100%
targeted
market
penetration
at
maturity
due
to
limited
competition |
 Verenium’s Expansion Pipeline: Targeted Markets
6
ANIMAL HEALTH
OILFIELD SERVICES
GRAIN PROCESSING
Current Markets
New Markets
BAKING
PERSONAL CARE
SWEETENERS
DETERGENTS /CLEANERS |
 Verenium as a Preferred Collaboration Partner in
Industrial Enzymes
7
•
OUR TECHNOLOGY
Industry leading technology for discovering and evolving
enzymes
•
OUR
FULL
SUITE
OF
CAPABILITIES
From
enzyme
discovery,
evolution,
expression through to commercial scale manufacturing
•
OUR
TRACK
RECORD
Demonstrated
ability
to
produce
high-performance
products in competitive fields
•
OUR
PARTNERING
HISTORY
Successful
past
collaboration
partnerships
give
us insight into what works well
•
OUR
SMALL
SIZE
AND
FLEXIBILITY
Gives
us
flexibility
to
structure
collaboration partnerships to achieve success
•
OUR
SCARCITY
The
alternatives
to
Verenium’s
capabilities
are
limited
and
of a
completely different scale and business model |
 The
Diversified Company We Are Building 8
Current
Commercial
Products
Product
Pipeline and
Current
Commercial
Products
2012 Revenue
Medium Term Potential Revenue
Expansion
Pipeline
$2.5B+ market
opportunity from new
potential products for:
•Animal Health & Nutrition
•Oilfield Services
•Grain Processing
•Detergents & Cleaners
•Syrups & Sweeteners
•Personal Care
•Baking
Product Pipeline:
•
Defined target molecule
•
Implementing product development plan
Expansion Pipeline:
•
Collaboration partnership discussions in progress
•
Target molecule may or may not be defined
•
Product development plan under development |
 Verenium’s Growth Drivers
9
Core Technology and Assets
Commercial Products
Product Pipeline
•
8 currently targeted at 3
markets
•Animal Health &
Nutrition
•Grain Processing
•Oilfield Services
•
Up to $1B current
market opportunity
•
10 new product
candidates for currently
addressed markets
•
Select initial launches
expected to begin 2012-
2013
•
Broaden market
opportunity to up to
$1.4B by 2016
•
Identified candidates under
discussion with potential
collaborators
•
For current AND new
markets
•
Detergents and Cleaners,
Baking, Sweeteners,
Personal Care
•
Focused on the rapid
creation of products from our
enzyme collection
•
Secondary focus on enzyme
products from new discovery
and evolution programs
Product Pipeline
Expansion Pipeline |
 Verenium Corporation
Q2 2012 Earnings Call
August 6, 2012 |